APA (7th ed.) Citation

Huang, Y., Tang, S., Xu, X., Zeng, Y., He, X., Li, Y., . . . Chen, Y. (2020). No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study. Frontiers in pharmacology, 11, 1071. https://doi.org/10.3389/fphar.2020.01071

Chicago Style (17th ed.) Citation

Huang, Yin-Qiu, et al. "No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study." Frontiers in Pharmacology 11 (2020): 1071. https://doi.org/10.3389/fphar.2020.01071.

MLA (9th ed.) Citation

Huang, Yin-Qiu, et al. "No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study." Frontiers in Pharmacology, vol. 11, 2020, p. 1071, https://doi.org/10.3389/fphar.2020.01071.